Mecasermin
Also known as: rhIGF-1, recombinant human insulin-like growth factor-1, Increlex
Classification
Peptide
Regulatory Status
FDA-approved
Sources
2
Review
n/a
Overview
Mecasermin is recombinant human IGF-1 identical to endogenous IGF-1; it binds the IGF-1 receptor and mediates growth-promoting and insulin-like metabolic effects.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
People look up mecasermin (Increlex) as prescription rhIGF-1 for growth failure in children with severe primary IGF-1 deficiency or GH-gene-deletion neutralizing antibodies. Adult muscle-building and anti-aging uses are not labeled indications and lack controlled support.
Interactions & cautions
Drug interactions
insulin and other hypoglycemic agents — Additive hypoglycemia risk from insulin-like activity; labeled meal timing and glucose monitoring context apply. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw